Navigation Links
FDA Approves Label Update for PREZISTA® to Include 192-Week Data in HIV-1-Infected Adult Patients Starting Treatment
Date:10/21/2011

jury, including some fatalities, have been reported. A causal relationship with PREZISTA/ritonavir therapy has not been established

Appropriate laboratory testing should be conducted prior to initiating therapy with PREZISTA/ritonavir and patients should be monitored during treatment. Increased AST/ALT monitoring should be considered in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pretreatment elevations of transaminases, especially during the first several months of PREZISTA/ritonavir treatment. Evidence of new or worsening liver dysfunction (including clinically significant elevation of liver enzymes and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver tenderness, hepatomegaly) in patients on PREZISTA/ritonavir should prompt consideration of interruption or discontinuation of treatment

  • Severe Skin Reactions:  Severe skin reactions (0.4%), accompanied by fever and/or elevations of transaminases in some cases, Stevens-Johnson Syndrome (<0.1%), and toxic epidermal necrolysis (post-marketing experience) have been reported in patients receiving PREZISTA/ritonavir.  Discontinue PREZISTA/ritonavir immediately if signs or symptoms of severe skin reactions develop (including, but not limited to, severe rash or rash accompanied with fever, general malaise, fatigue, muscle or join aches, blisters, oral lesions, conjunctivitis, hepatitis and/or eosinophilia).

  • In clinical trials (N=3063), rash (all grades, generally mild to moderate, regardless of causality) occurred in 10.3% of patients receiving PREZISTA/ritonavir. Discontinuation due to rash was 0.5%

  • Sulfa Allergy: PREZISTA should be used with caution in patients with known sulfonamide allergy
  • Diabetes Mellitus/Hyperglycemia and Hemophilia: New-onset or exacerbations of preexisting diabetes mellitus, hyperglycemia, and increased bleeding in hemophiliacs have been reported in patients re
    '/>"/>

  • SOURCE Janssen Therapeutics, Division of Janssen Products, LP
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
    2. FDA Approves Combination Therapy Juvisync
    3. FDA Approves Cialis to Treat Benign Prostatic Hyperplasia
    4. FDA Approves Remicade to Treat Ulcerative Colitis in Children Older Than 6 Years
    5. FDA Approves Soliris for Rare Pediatric Blood Disorder
    6. FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
    7. FDA Approves Xalkori with Companion Diagnostic for a Type of Late-stage Lung Cancer
    8. FDA Approves Firazyr To Treat Acute Attacks of Hereditary Angioedema
    9. FDA Approves Adcetris to Treat Two Types of Lymphoma
    10. FDA Approves the First Specific Treatment for Scorpion Stings
    11. Cardinal Health Board of Directors Approves Cash Dividend, Elects David P. King as Director
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... -- Lockton Dunning Benefits, the Dallas ... of Vice President Kim Foerster on ... team, Excelsior Solutions. Foerster brings ... position.  Most recently, she worked as the Director ... where she has held various managerial positions since ...
    (Date:12/24/2014)... Calif. , Dec. 23, 2014 In response ... Doctors, Association of Sierra Leone , Direct ... Leone for the treatment of local health workers ... While a new dedicated Ebola care center was constructed for ... the facility is not available for local Sierra Leonean health ...
    (Date:12/22/2014)... 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical care ... technology to help fight deadly inflammation in critically-ill ... today announced the appointment of Dr. Gregory ... Senior Vice President of Clinical Development, effective January ... Russo is an accomplished pediatric cardiothoracic surgeon ...
    Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
    ... Process Seals recently expanded its portfolio of ethylene ... material specifically developed to meet the requirements of hygienic ... biotech industries. The white 70 EPDM 253815 ... and butterfly valve seals in hygienic applications where cleanliness ...
    ...  SCOLR Pharma, Inc. (OTCQB: SCLR) announced today that it ... to buy" details for their products currently available.  The ... found on www.scolr.com under the "Specialty Supplements" ... from the home page or the navigation bar at ...
    Cached Medicine Technology:Process Seals Develops White Hygienic Sealing Material for Pharmaceutical, Food and Beverage, and Biotech Applications 2SCOLR Pharma, Inc. Provides Product Information on Website 2
    (Date:12/26/2014)... Angeles, CA (PRWEB) December 26, 2014 ... power score of 3.1 out of 5. This score ... a low level of product specialization, low switching costs ... power is reduced by the low availability of substitutes ... the world price of steel and aluminum, key inputs ...
    (Date:12/26/2014)... “Many people become overwhelmed by the thought of ... phone calls with insurance companies,” The Jones Firm explains ... free eBook on pedestrian and bicycle accidents . ... auto accident claims assures the injured individual that a ... their case while they focus on recovering. , ...
    (Date:12/26/2014)... Phoenix, AZ (PRWEB) December 26, 2014 ... dependable source for the best in heating, cooling ... demand for 24 hour emergency services in 2014 ... customers alike know that Arizona is known for ... contractor company that understands the intricacies and details ...
    (Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) – ... the current treatment landscape, unmet needs, current pipeline ... Stivarga is a drug which is used in ... Ingelheim is developing nintedanib (BIBF-1120), an orally available ... in the US, Europe, and Japan. The drug ...
    (Date:12/25/2014)... 2014 Recently, iFitDress.com, the popular online supplier ... announced its new selection of black one-shoulder cocktail dresses ... now; they are available at discounted prices, up to 70% ... will last for three weeks only. You know, we have ... are interested in our new items can visit our website ...
    Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
    ... the first large scale, multiethnic study of its kind, ... three particular molecules known as cytokines as a cause ... molecules as early biological markers that may be used ... apparently healthy individuals. , Reporting in the August 15 ...
    ... this weeks press release: , , Could anemia be used ... Translating pharmacogenomics: challenges on the road to the clinic, , ... links below to take your readers straight to the online ... Could anemia be used to assess the burden and control ...
    ... us rely on the bathroom scale to tell us when ... better to keep a tape measure at the ready. New ... body weight still falls within a normal rangemarkedly increases the ... heart and the rest of the body. , The research, ...
    ... used to prevent cluster headaches can cause heart problems, ... 2007, issue of Neurology, the medical journal of the ... for cluster headaches should be closely monitored with frequent ... Cluster headache is a rare, severe form of headache ...
    ... have a higher risk of developing late age-related macular ... a report in the July issue of Archives of ... macular degeneration (AMD) [a progressive eye disease that affects ... cause of blindness in the Western world, according to ...
    ... HOUSTON - When molecular disaster strikes, causing structural damage ... each other to help contain the wreckage, scientists at ... report in the August edition of Cell. , This ... control and a pathway known as chromatin remodeling "opens ...
    Cached Medicine News:Health News:UCLA researchers identify markers that may predict diabetes in still-healthy people 2Health News:UCLA researchers identify markers that may predict diabetes in still-healthy people 3Health News:Anemia and tropical diseases; Is pharmacogenomics ready for the clinic? 2Health News:Pot bellies linked to early signs of cardiovascular disease 2Health News:Pot bellies linked to early signs of cardiovascular disease 3Health News:Drug for cluster headaches may cause heart problems 2Health News:Smoking may strongly increase long-term risk of eye disease 2Health News:Chromatin remodeling complex connected to DNA damage control 2
    ... pro Electronic Pipette is ideal for all ... easy-to-follow display, ergonomically-placed operating buttons, and various ... pipetting and diluting make this a lab ... of a manual pipette without any adverse ...
    ... , , The Shortyavailable with both Impact and ... face-to-face relationship with the scientific community generates a ... easier and more effective., Shorter and lighter ... you closer to the working area for ...
    ... Powerful and Flexible Impact And Impact2 ... different volume ranges, our single channel Impact ... demands of any application. Engineered with the ... our multichannel line, these pipettors are equally ...
    ... and Flexible Impact And Impact2 Pipettors ... ranges, our single channel Impact and Impact2 ... any application. Engineered with the same ergonomic ... line, these pipettors are equally easy to ...
    Medicine Products: